Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EQUILIBRIUM-ADCS
NL-OMON61651Phase 3Not yet recruiting
- Sponsor
- Crinetics Pharmaceuticals
- Start
- Oct 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of atumelnant in ACTH-dependent Cushing's syndrome and Corticotropin adenoma (ACTHoma) (3 arms), sponsored by Crinetics Pharmaceuticals. Primary endpoint: Proportion of participants with mUFC less than or equal to ULN at Week 12. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
atumelnant
03
Conditions
ACTH-dependent Cushing's syndromeCorticotropin adenoma (ACTHoma)
Beyond the preview
Go deeper on NL-OMON61651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61651.